VIR YOLO ahead of Phase 3 results - 280k $
$VIR
AI SUMMARY — User is making a large bet on Vir Biotechnology (VIR) ahead of Phase 3 clinical trial results, expecting positive news to drive significant upside. Key risks include trial failure, regulatory setbacks, or market disappointment that could result in substantial losses on the concentrated position.
| TICKER | VIR |
USER | u/ElectricalJeweler587 |
| RATING |
BULLISH |
ENTRY |
$10.47
|
| POSITION |
955 sh
SYN
|
BOOK VAL |
$10000.00 |
| CURRENT |
$10.47 |
P&L % |
+0.00%
|
| CURR VAL |
$10000.00 |
P&L $ |
+0.00
|